Revvity Signals - Drug Discovery

News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

EuMentis Therapeutics Receives FDA Approval to Begin Phase 2 Trial of EM-221 for Schizophrenia

Thursday, July 31, 2025

EuMentis Therapeutics a clinicalstage pharmaceutical company developing treatments for schizophrenia and other central nervous system CNS disorders has received clearance from the US Food and Drug Administration

AstraZeneca and Revna Biosciences Broaden Access to Lung Cancer Treatment in Ghana

Thursday, July 31, 2025

AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care in Ghana through their ongoing collaboration Since announcing their partnership in April both organisations have worked togethe

Calidi Biotherapeutics Granted FDA Fast Track Designation for CLD-201, an Innovative Viral Therapy for Soft Tissue Sarcoma

Wednesday, July 30, 2025

Calidi Biotherapeutics Inc a clinicalstage biotechnology company focused on developing targeted treatments using genetic medicine delivery systems has received Fast Track designation from the US Food and Drug Administration FDA

Bio Usawa and Sartorius Stedim Biotech Partner to Advance Biopharmaceutical Manufacturing in Africa

Wednesday, July 30, 2025

Bio Usawa Biotechnology Ltd an African biotechnology company has partnered with Sartorius Stedim Biotech a global biopharmaceutical manufacturing solutions provider to strengthen Africas biopharmaceutical sector

Boehringer Ingelheim and Re-Vana Therapeutics Partner to Develop Long-Acting Eye Treatments

Tuesday, July 29, 2025

Boehringer Ingelheim has entered into a strategic collaboration and licensing agreement with ReVana Therapeutics a company based in the US and UK that specialises in ocular therapies and drug delivery technologies

Zymeworks Receives FDA Clearance for Investigational Drug ZW251 to Treat Liver Cancer

Tuesday, July 29, 2025

Zymeworks Inc a clinicalstage biotechnology company has announced that the US Food and Drug Administration FDA has cleared its Investigational New Drug IND application for ZW

Candel Therapeutics Gains EMA Orphan Designation for CAN-2409 in Pancreatic Cancer Treatment

Friday, July 25, 2025

Candel Therapeutics a clinicalstage biopharmaceutical company has been granted Orphan Designation by the European Medicines Agency EMA for its investigational therapy CAN aglatimagene besadenovec

Sarclisa Gains EU Approval for Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

Friday, July 25, 2025

Sanofi has received approval from the European Commission for the use of Sarclisa isatuximab in combination with bortezomib lenalidomide and dexamethasone VRd as an induction treatment for adults newly diagnosed

Solid Biosciences Secures FDA Fast Track Designation for Gene Therapy Candidate SGT-501 Targeting CPVT

Thursday, July 24, 2025

Solid Biosciences has received Fast Track designation from the US Food and Drug Administration FDA for SGT its investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia

New England Biolabs Launches Low-Bias Small RNA Library Prep Kit to Improve RNA Diversity Analysis

Wednesday, July 23, 2025

New England Biolabs NEB has introduced the NEBNext Lowbias Small RNA Library Prep Kit a new solution designed to reduce bias in small RNA sequencing and better reflect the true diversity of RNA species in research samples